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Abstract Thymoma and thymic carcinoma are thymic epi-
thelial tumors (TETs). We performed a molecular profiling
to investigate the pathogenesis of TETs and identify novel
targets for therapy. We analyzed 37 thymomas (18 type A,
19 type B3) and 35 thymic carcinomas. The sequencing of
50 genes detected nonsynonymous mutations in 16 carcino-
mas affecting ALK, ATM, CDKN2A, ERBB4, FGFR3, KIT,
NRAS and TP53. Only two B3 thymomas had a mutation in
noncoding regions of the SMARCB1 and STK11 gene re-
spec t ive ly. Three type A thymomas harbored a
nonsynonymous HRAS mutation. Fluorescence in situ hy-
bridization detected in 38 % of carcinomas a CDKN2A, in
32 % a TP53 and in 8 % an ATM gene deletion, whereas only
one B3 thymoma exhibited a CDKNA deletion, and none of
the type A thymomas showed a gene loss. Sequencing of the
total miRNA pool of 5 type A thymomas and 5 thymic carci-
nomas identified the C19MC miRNA cluster as highly
expressed in type A thymomas, but completely silenced in
thymic carcinomas. Furthermore, the miRNA cluster
C14MC was downregulated in thymic carcinomas. Among
non-clustered miRNAs, the upregulation of miR-21, miR-9-
3 and miR-375 and the downregulation of miR-34b, miR-34c,
miR-130a and miR-195 in thymic carcinomas were most sig-
nificant. The expression of ALK, HER2, HER3, MET,
phospho-mTOR, p16INK4A, PDGFRA, PDGFRB, PD-L1,
PTEN and ROS1 was investigated by immunohistochemistry.
PDGFRAwas increased in thymic carcinomas and PD-L1 in
B3 thymomas and thymic carcinomas. In summary, our results
reveal genetic differences between thymomas and thymic car-
cinomas and suggest potential novel targets for therapy.
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Introduction
Thymic epithelial tumors (TETs) are rare mediastinal tumors.
The WHO classification distinguishes type A, AB, B1, B2 and
B3 thymomas and rare other subtypes from thymic carcinomas
[1]. TypeA andAB thymomas aremostly benign, whereas type
B1, B2 and B3 thymomas are more aggressive, with B3
thymomas having the greatest tendency formostly intrathoracic
spread.Thymic carcinomaon the contrary is a highly aggressive
tumor with frequent lymphatic and hematogenous metastasis.
The therapy is based on surgery and in cases of spread or
incomplete resection on chemo- and radiotherapy [2]. The
development of molecularly targeted drugs has so far been
limited by the lack of information on the molecular alterations
of TETs and the rarity of the disease. Mutation of the tyrosine
kinase KITwas the only known targetable alteration in thymic
carcinoma, but it is present in only 6–12 % of cases [3, 4].
Recently, whole exome and targeted gene panel sequencing of
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TETs identified a specific missense mutation in GTF2I in type
A thymomas and common mutations in TP53 and epigenetic
regulatory genes in thymic carcinomas [5–8].
We performed a molecular profiling study to derive further
insight into the pathogenesis of TETs and to identify potential
novel targets for therapy. We focused the analysis on B3
thymomas and thymic carcinomas, because of their aggres-
siveness and due to the need to improve therapy. The analysis
of type A thymomas served for comparison to elucidate mo-
lecular alterations that may be associated with aggressivenes.
An additional genetic analysis of subtypes AB, B1 and B2
would have been hampered by the abundant presence of nor-
mal thymocytes in these subtypes, which impedes mutation
detection and miRNA profiling.
We carried outDNA sequencing of typeA andB3 thymomas
and thymic carcinomas with a panel of 50 genes comprising
oncogenes and tumor suppressor genes known to be frequently
altered in various tumors. Currently, such gene panels are in-
creasingly utilized in diagnostic molecular pathology for the
identification of therapeutic targets in various malignancies.
Such a panel sequencing is feasible with formalin fixed, paraffin
embedded tissue, which is not well suited for exome sequenc-
ing, which in turn requires frozen tissue that is often not avail-
able in routine histopathology diagnostics. We complemented
the genetic tumor profiling with sequencing the total miRNA
pool of 5 type A thymomas and 5 thymic carcinomas for which
unfixed, frozen tissue was available. Furthermore, we explored
the thymomas and thymic carcinomas with a panel of immuno-
histochemical stains for antigens (ALK, HER2, HER3, MET,
phospho-mTOR, p16INK4A, PDGFRA, PDGFRB, PD-L1,
PTEN, and ROS1) that might constitute putative targets for
therapy and fluorescence in situ hybridization for ALK, ATM,
CDKN2A, FGFR3 and TP53, to detect rearrangements and/or
numerical aberrations of these genes.
Materials and Methods
Tissue Samples
Formalin fixed, paraffin embedded type A (n = 18) and B3
(n = 19) thymoma, thymic carcinoma (n = 35; 34 squamous
cell carcinomas, 1 lymphoepithelioma-like carcinoma) and
non-neoplastic thymus (n = 6) tissues were retrieved from
the archive of the Department of Pathology, Medical
University Vienna. For miRNA sequencing unfixed frozen
tissues of 5 type A thymomas and 5 thymic squamous cell
carcinomas stored in liquid nitrogen were utilized. The tumors
were diagnosed and subtyped according to the WHO classifi-
cation [1]. The study was approved by the ethics commitee of
the Medical University Vienna (projects 1167/15, 1259/15
and 1794/15).
Cancer Gene Panel Sequencing
DNAwas extracted from paraffin embedded tissue blocks with
a QIAamp Tissue Kit™ (Qiagen, Hilden, Germany). 10 ng
DNA per sample were utilized for sequencing. The DNA li-
brary was generated by multiplex polymerase chain reaction
(PCR) with the Ion AmpliSeq Cancer Hotspot Panel v2™
(Life Technologies, Carlsbad, CA). This panel covers mutation
hotspots of 50 genes, mostly oncogenes and tumor suppressor
genes that are frequently mutated in tumors. Template prepara-
tion was carried out by emulsion PCRwith Ion One Touch™ or
Ion Chef™ instruments (Life Technologies). Sequencing was
performed with an Ion Torrent PGM™ (Life Technologies).
Sequencing data were analyzed using Variant Caller™, Ion
Reporter™ (both from Life Technologies) and the VARIFI soft-
ware developed by the Center for Integrative Bioinformatics
Vienna. Nonsynonymous mutations detected with the Ion
Torrent PGM™ were verified by capillary sequencing. PCR
primers flanking the DNA mutation were designed. The DNA
was amplified by PCR with Jump Start™ REDtaqR Ready
Mix™ (Sigma-Aldrich, Vienna, Austria). PCR products were
cleaned using ExoSAP-IT (Affymetrix, Santa Clara, CA). The
sequencing of PCR products was carried out with the BigDyeR
Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems,
Waltham, MA). The resulting DNA fragments were purified
with the DyeEx 96 Kit (Qiagen) and sequenced with a 3500
Genetic Analyzer (Applied Biosystems). For sequence analysis
we employed the SeqScape Version 2.7 software (Applied
Biosystems). In TETs with nonsynonymous mutations detected
by panel and capillary sequencing DNA from normal tissue of
the patients was also sequenced to exclude rare polymorphisms.
miRNA Sequencing
MiRNA was isolated from unfixed, frozen type A thymoma
and thymic carcinoma tissues with a PureLink™ miRNA
Isolation Kit (Invitrogen, Carlsbad, CA). The miRNA concen-
tration was determined using a QubitR microRNA assay kit and
a QubitR fluorometer (Thermo Fisher, Waltham,MA). The size
distribution of themiRNAswas validatedwith anAgilent small
RNA kit and anAgilent Bioanalyzer instrument (Agilent, Santa
Clara, CA). miRNA libraries for sequencing were generated
with a Ion Total RNA Seq Kit (Thermo Fisher). Template prep-
aration was achieved with the Ion PGM™ IC 200 Kit on an Ion
Chef instrument (Thermo Fisher). Sequencing was performed
using the Ion PGM™ Sequencing 200 Kit on an Ion Torrent
PGM with Ion 316 chips (Thermo Fisher). An initial adapter
trimming of sequencing reads was performed with the Torrent
Suite™ software (Thermo Fisher). The sequences were then
converted to fastq format and exported for further analysis in
the CLC™ Genomics Workbench 8.5 (Qiagen, Hilden,
Germany). As recommended by the manufacturer, a second
adapter trimming was performed, followed by quality
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trimming, and mapping to miRBase v21. Quality control of
these fastq files was conducted using FastQC. To identify pos-
sible RNA degradation, the reads were also mapped against
human rRNA and tRNA sequences.
Fluorescence In Situ Hybridization (FISH)
FISHwas performedwith 4μm thin sections of type A and B3
thymoma and thymic carcinoma tissue microrrays. The arrays
were generated with a manual tissue arrayer from Beecher
Instruments (Sun Prairie, WI). Three tissue cores 0.8 mm in
diameter each were taken per tumor. The following FISH
probes were employed: ALK (2p23.1; Abbott, Abbott Park,
IL), ATM (11q22), CDKN2A (9p21)/Centromer 9, FGFR3
(4p16), PTEN (10q23.31)/Centromer 10, TP53 (17p13)/
Centromer 17 (Metasystems, Altlussheim, Germany) and
ROS1 (Zytovision, Bremerhaven, Germany). 200 cell nuclei
per tumor were evaluated. A hetero-/homozygous gene dele-
tion or aneuploidy was concluded when more than 25 % of
nuclei showed relevant aberrant fluorescence signals.
Immunohistochemistry
Immunohistochemistry was performed using tissue arrays of
type A and B3 thymomas and thymic carcinomas. 2 μm sec-
tions of the tissue arrays were stained on a Ventana Benchmark
Ultra (Ventana, Tucson, AZ) with extended heat-induced epi-
tope retrieval with CC1 buffer and the ultraView Universal
DAB Detection Kit (Ventana). The following antibodies were
employed: ALK (clone 1A4; Zytomed, Berlin, Germany),
HER2 (clone 4B5; Ventana), HER3 (clone SP71; Abcam,
Milton, UK), MET (clone SP44; Ventana), phospho-mTOR
(clone 49F9; Cell Signalling, Danvers, MS), p16INK4A (clone
E6H4; Ventana), PDGFRA (rabbit polyclonal; Thermo Fisher
Scientific), PDGFRB (clone 28E1, Cell Signalling), PD-L1
(clone E1L3N; Cell Signalling), PTEN (clone Y184; Abcam)
and ROS1 (c lone D4D6; Ce l l S igna l l i ng ) . An
immunohistochemial score was determined by multiplying
the percentage of positive cells by their respective staining
intensity (0 = negative, 1 = weak, 2 = moderate, 3 = strong).
Immunohistochemical score (maximum 300) = (% negative x
0) + (% weak x 1) + (% moderate x 2) + (% strong x 3).
Statistics
MiRNA sequencing data were analyzed in a CLC Genomics
Workbench (Qiagen) with an embedded version of EdgeR [9].
To correct for multiple testing, the false discovery rate method
(FDR) was used. A FDR below 0.05 was defined as differen-
tially expressed. Graphs, plots and heatmaps were created
with Microsoft Excel, CLC Genomics Workbench, and IBM
SPSS Statistics 20. Immunohistochemistry results were eval-
uated employing the Shapiro-Wilk, Kolmogorov-Smirnoff
and Kruskal-Wallis tests. Patient survival data were deter-
mined using the Kaplan-Meier estimator and significances
were calculated by the log-rank and Breslow tests.
Results
Targeted Cancer Gene Sequencing Reveals Genetic
Differences Between Thymoma and Thymic Carcinoma
and Identifies Potential Novel Targets for Therapy
We sequenced mutation hotspot regions of 50 genes that are
known to be frequently mutated in various human cancers. A
total of 35 thymic carcinomas, 19 type B3 thymomas and 18
type A thymomas were analyzed. In 16 (46 %) thymic carci-
nomas a nonsynonymous mutation was detected that is pre-
dicted to alter the amino acid sequence of the encoded protein
(Tables 1 and 2). The most frequently altered gene was TP53
which was mutated in 9 carcinomas, with one case harboring
two TP53 mutations. Four carcinomas exhibited a missense
mutation in the tumor suppressor CDKN2A, which was thus
the second most frequently mutated gene. Two carcinomas
each harbored a missense mutation in the fibroblast growth
factor receptor 3 (FGFR3) and the receptor tyrosine kinase
KIT. The receptor tyrosine kinases ALK and ERBB4, the
serine/threonine kinase ATM, and the GTPase NRAS were
mutated in one thymic carcinoma each (Tables 1 and 2).
The B3 thymomas did not harbor any of the mutations
detected in thymic carcinomas. Only in two (11 %) B3
thymomas a mutation was detected (Tables 1 and 2). One
was a point mutation in the 3′ untranslated region at position
−17 of the tumor suppressor SMARCB1. The other represent-
ed a deletion of two nucleotides +16 and +17 upstream of the
exon-intron boundary of exon 4 of the tumor suppressor
STK11. At present it is unknown wether these mutations have
Table 1 Genes mutated in type A and B3 thymomas and thymic
carcinomas
Mutated genes Number of mutated cases
Type A thymoma (n = 18) HRAS 3
Type B3 thymoma (n = 19) SMARCB1 1
STK11 1
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any effect on gene function, in particular on RNA translation
or RNA splicing.
Three (17 %) of the 18 type A thymomas harbored a non-
synonymous mutation in the HRAS oncogene (Tables 1 and
2). One of these thymomas (case 3, Table 2) was a
histomorphologically atypical variant type A thymoma [10]
with a lung metastasis.
Fluorescence In Situ Hybridization (FISH) - Frequent
Loss of CDKN2A and TP53 in Thymic Carcinomas
DNA sequencing revealed TP53 and CDKN2A as the most
frequently mutated genes in thymic carcinomas and detected
one case of ATM mutation. We therefore performed FISH to
determine wether additional deletions of these tumor suppres-
sor genes were present. A total of 28 thymic carcinomas were
analyzed for a loss of TP53. Nine (32 %) exhibited a hetero-
zygous or mixed heterozygous/homozygous deletion of TP53
(Table 3). In 4 cases a heterozygous deletion was associated
with a mutation of the remaining TP53 allele. Twelve of 32
(38 %) analyzed thymic carcinomas exhibited a loss of the
CDKN2A gene, which was heterozygous in three, homozy-
gous in four and mixed heterozygous/homozygous in five
cases (Table 3). Cause specific survival, freedom of recur-
rence, disease free and overall survival of thymic carcinomas
with a CDKN2A (Supplementary Fig. S1) or TP53
(Supplementary Fig. S2) gene alteration (mutation and/or de-
letion) did not differ from wild-type cases. A TP53 gene loss
was not present in 17 B3 thymomas analyzed. Only in one of
17 (6 %) B3 thymomas a mixed heterozygous/homozygous
CDKN2A gene deletion was detected. In type A thymomas,
no TP53 and CDKN2A deletions were present (Table 3). A
heterozygous deletion of ATM was noted in two (8 %) of 26
thymic carcinomas. None of them harbored an ATMmutation
by gene sequencing. In type A and B3 thymomas no ATM
loss was found (Table 3).
Motivated by the two thymic carcinomas with an FGFR3
mutation and the one carcinoma with an ALK mutation, we
also performed FISH for these two genes. However a FGFR3
amplification or ALK translocation was not detected in 25 and
Table 2 Mutations in type A and B3 thymomas and thymic carcinomas
Case Tumor Gene Gene region Chromosome position cDNA Protein variant Variant frequency
1 A thymoma HRAS Exon 3 chr11:533874 c.182A>G p.Q61R 46 %
2 A thymoma HRAS Exon 3 chr11:533874 c.182A>G p.Q61R 59 %
3 A thymoma HRAS Exon 2 chr11:534276 c.47A>C p.K16T 48 %
4 B3 thymoma SMARCB1 3′UTR chr22:24176384 c.1185-17C>T unknown 55 %
5 B3 thymoma STK11 Intron 3 chr19:1220354 c.1580 + 16_17del unknown 59 %
6 Carcinoma TP53 Exon 1 chr17:7578383 c. 529_546del p.45_50delPHHERC 87 %
7 Carcinoma TP53 Exon 8 chr17:7577085 c. 853C>T p.E285K 50 %
8 Carcinoma CDKN2A Exon 2 chr9:21971029 c.329G>A p.W110* 63 %
9 Carcinoma CDKN2A Exon 2 chr9:21971029 c. 329G>A p.W110* 81 %
FGFR3 Exon 7 chr4:1803568 c. 746C>G p.S249C 42 %
10 Carcinoma TP53 Exon 8 chr17:7577129 c.692T>C p.F231S 60 %
11 Carcinoma TP53 Exon 10 chr17:7574029 c.998G>A p.R333H 51 %
12 Carcinoma CDKN2A Exon 2 chr9:21971186 c.172C>T p.R58* 95 %
TP53 Exon 2 chr17:7578211 c.638G>A p.R213Q 81 %
13 Carcinoma FGFR3 Exon 9 chr4:1806099 c.1118A>G p.Y373C 35 %
14 Carcinoma CDKN2A Exon 2 chr9:21971117 c.241C>T p.P81S 47 %
TP53 Exon 8 chr17:7577085 c.853G>A p.E285K 48 %
15 Carcinoma KIT Exon 17 chr4:55599342 c.2468A>C p.Y823S 48 %
16 Carcinoma ALK Exon 25 chr2:29432664 c.3824C>T p.R1275Q 25 %
TP53 Exon 5 chr17:7578457 c.473 C>T p.R158H 49 %
17 Carcinoma KIT Exon 11 chr4:55593661 c.1727T>C p.L576P 37 %
18 Carcinoma ERBB4 Exon 9 chr2:212576901 c.998C>T p.A333V 46 %
19 Carcinoma NRAS Exon 3 chr1:115256528 c.183T>A p.Q61H 35 %
TP53 Exon 5 chr17:7578423 c.507 C>T p.M169I 87 %
TP53 Exon 8 chr17:7577085 c.853 C>T p. E285K 79 %
20 Carcinoma ATM Exon 8 chr11:108117798 c.1009 C>T p.R337C 53 %
21 Carcinoma TP53 Exon 10 chr17:7574003 c.1024C>T p.R342* 49 %
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27 evaluated thymic carcinomas, respectively (data not
shown).
miRNA Sequencing Identifies Differential miRNA
Expression in Type A Thymoma and Thymic Carcinoma
The expression of 1218 different miRNAs was detected in
type A thymomas and thymic carcinomas. 113 of the
miRNAs were differentially expressed between the two tumor
entities at a false discovery rate corrected p-value of below
0.05 (Fig. 1). Sixtythree of these 113 miRNAs were part of
two large imprinted miRNA clusters on chr19q13.4 and
chr14q32, called C19MC and C14MC, respectively. C19MC
miRNAs were highly expressed in 4 of the 5 type A
thymomas and completely silenced in all 5 thymic carcinomas
(Fig. 2). C14MC transcripts were also significantly downreg-
ulated in thymic carcinomas, but the cluster was not complete-
ly silenced (Fig. 3). Fifty of the differentially expressed
miRNAs were not clustered. Amongst them, most significant
was the strong expression of miR21, miR-9-3 and miR-375 in
thymic carcinomas and their very low abundance in type A
thymomas (Fig. 4). On the contrary miR-34b, miR-34c, miR-
130a and miR-195 were of low abundance in thymic carcino-
mas, but strongly expressed in type A thymomas (Fig. 5).
Immunhistology Identifies PDGFRA and PD-L1
as Potential Therapeutic Targets in Thymic Carcinoma
and B3 Thymoma
Type A and B3 thymoma and thymic carcinoma tissues were
stained with antibodies to ALK, HER2, HER3, MET,
phospho-mTOR, PDGFRA, PDGFRB, PD-L1, p16INK4A,
PTEN and ROS1 to identify potential targets for therapy.
The tumor cells did not express ALK, HER2, and HER3
(Table 4).
A weak MET expression was noted in only two (13 %) of
15 type A thymomas. B3 thymomas and thymic carcinomas
did not express MET.
The expression of phospho-mTOR was similar in type A
and B3 thymomas and thymic carcinomas (Table 4).
The expression of PDGFRAwas significantly increased in
thymic carcinomas as compared to type A and B3 thymomas
(Table 4, Fig. 6, Supplementary Fig. S3). A low PDGFRB
expression was noted in 40 % of type A and 12 % of B3
thymomas. Thymic carcinomas were PDGFRB negative
(Table 4).
The immune check point inhibitor PD-L1 was expressed in
only 2 (13 %) of 15 type A thymomas, but 13 (76 %) of 17 B3
thymomas and 16 (53 %) of 30 thymic carcinomas (Table 4,
Fig. 7, Supplementary Fig. S4). The expression of PD-L1 in
thymic carcinomas did not correlate with a difference in cause
specific survival, freedom of recurrence, disease free and
overall survival (Supplementary Fig. S5).
In six non-neoplastic thymi of adult individuals, analyzed
for comparison with TETs, p16INK4A expressing epithelial
cells were scarce and located in close vicinity to Hassall’s
corpuscles (data not shown). In TETs, 10 (67 %) of 15 type
A thymomas and 14 (47 %) of 30 thymic carcinomas
expressed p16INK4A, wheras only one of 17 (6 %) B3
thymomas exhibited a low p16INK4A positivity (Table 4,
Fig. 8). In thymic carcinomas, but not in type A and B3
thymomas, a lack of p16INK4A expression was largely associ-
ated with CDKN2A mutation or gene deletion (data not
shown). The expression of p16INK4A did not correlate with a
difference in cause specific survival, freedom of recurrence,
disease free and overall survival in thymic carcinomas
(Supplementary Fig. S6).
The expression of PTEN was heterogenous, with no sig-
nificant differences between the three tumor entities (Table 4).
A lack of PTEN expression was noted in one B3 thymoma
Table 3 Fluorescence in situ
hybridization. ATM, CDKN2A
and TP53 gene deletions in type













A thymoma (n = 15) ATM 0 0 0 0 %
B3 thymoma (n = 17) ATM 0 0 0 0 %
Thymic carcinoma
(n = 26)
ATM 2 0 0 8 %
A thymoma (n = 14) CDKN2A 0 0 0 0 %
B3 thymoma (n = 17) CDKN2A 0 0 1 6 %
Thymic carcinoma
(n = 32)
CDKN2A 3 4 5 38 %
A thymoma (n = 15) TP53 0 0 0 0 %
B3 thymoma (n = 17) TP53 0 0 0 0 %
Thymic carcinoma
(n = 28)
TP53 8 0 1 32 %
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and one thymic carcinoma. However, both tumors retained
two PTEN signals as assessed by FISH (data not shown).
Thus, the lack of PTEN expression was not caused by gene
deletion, but by another mechanism, presumably PTEN pro-
moter methylation.
A low ROS1 expression was present in 3 (20 %) of 15 type
A thymomas, but none of them harbored a ROS1 gene trans-
location as assessed by FISH (data not shown). B3 thymomas
and thymic carcinomas were ROS1 negative (Table 4).
Discussion
By gene panel and miRNA sequencing, FISH and immuno-
histochemistry we found genetic differences between
thymoma (type A and B3) and thymic carcinoma and identi-
fied potential novel targets for therapy.
The most frequently altered gene was the tumor suppressor
CDKN2A. It encodes p16INK4A and p14ARF by alternative
splicing. p16INK4A inhibits cell cycle progression by blocking
cyclin dependent kinases 4 and 6, whereas p14ARF activates
the TP53 tumor suppressor. A CDKN2A alteration may lead
to activation of cyclin dependent kinases. Inhibitors for these
kinases are currently being investigated in clinical trials for
various malignancies and might constitute a therapeutic op-
tion also for thymic carcinomas [11]. In a previous work by
Petrini I. et al. a lack of p16INK4A protein expression identified
TETs with a worse disease related survival [12]. In our study,
however, CDKN2A gene loss or mutation did not correlate
with a worse outcome in thymic carcinomas.
The second most frequently altered gene in thymic carcino-
maswas the tumor suppressor TP53.ATP53 protein overexpres-
sion, which is often caused by TP53mutation, has been reported
in a cohort of 25 thymic carcinomas to be associatedwith aworse
disease free survival [7]. In our study with 31 evaluable thymic
carcinomas TP53 gene loss or mutation was, however, not a
prognostic marker for disease free or overall survival.
The tyrosine kinase KIT is the receptor for stem cell factor.
It contributes to the growth and survival of tumors and is best
known for its involvement in the pathogenesis of gastrointes-
tinal stromal tumors [13]. Mutated KIT constitutes a therapeu-
tic target for kinase inhibitors such as imatinib. KIT mutation
is rare in thymic carcinoma, but so far the only known molec-
ular target based on few, but encouraging case reports [14, 15].
In our series two carcinomas with KIT mutations that predict
sensitivity to imatinib were present.
The FGFR family includes four receptor tyrosine kinases.
FGFR genes are deregulated in solid tumors by amplification,
translocation or mutation [16]. FGFR3 mutations are
particulary frequent in bladder cancer, where they are associ-
ated with low grade, early stage, and better survival [17]. We
observed a FGFR3 missense mutation in two thymic carcino-
mas. Thus, inhibition of FGFR3might represent a novel target
in a subset of thymic carcinomas. Several FGFR inhibitors are
currently in development and being evaluated in clinical trials
[16, 18].
Fig. 2 Heatmap showing high
C19MC miRNA cluster
expression in four of five type A
thymomas, but virtually no
expression in thymic carcinomas
at a false discovery rate p-
value < 0.0005
Fig. 1 Heatmap of all miRNA transcripts differentially expressed in type
A thymomas and thymic carcinomas at a false discovery rate p-
value < 0.05
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ALK is a receptor tyrosine kinase that, when altered by
chromosomal inversion, translocation, amplification or muta-
tion, plays an oncogenic role in certain cancers. Best known
are ALK gene alterations in anaplastic large cell lymphoma,
lung adenocarcinoma, inflammatory myofibroblastic tumor
and neuroblastoma [19]. The p.R1275Q ALK mutation ob-
served in one of our thymic carcinomas is an activating point
mutation in the kinase domain and known as one of the most
common mutations in neuroblastoma [20]. We did not detect
an ALK rearrangement or amplification in TETs by FISH. An
ALK mutation had also been detected by Petrini I. et al. in an
AB and a B3 thymoma by exome and panel sequencing [5].
Small molecule inhibitors such as crizotinib, that target the
kinase activity of ALK, are established in the clinic and might
be a novel therapeutic in ALK mutated TETs as well.
The epidermal growth factor receptor family includesEGFR,
ERBB2 (also known asHER2), ERBB3 (also known asHER3)
and ERBB4. Therapy of colon and breast cancer with anti-
EGFR and anti-ERBB2 antibodies, respectively, and of EGFR
mutated lung adenocarcinoma with tyrosine kinase inhibitors is
well established [21]. ERBB4mutations have been identified in
lung, breast and gastric cancer and melanoma. Several of these
ERBB4 mutations were shown to be oncogenic in melanoma
models and could be inhibited by treatment with lapatinib [22].
ERBB4 mutated thymic carcinoma might also be inhibited by
EGFR family blockers such as lapatinib and afatinib [21].
Fig. 3 Heatmap showing
different expression of C14MC
miRNA cluster members in type
A thymomas and thymic
carcinomas at a false discovery
rate p-value < 0.05
p=0,0099
p=0,00006 p=0,0361
Fig. 4 Non-clustered miRNAs
with stronger expression in
thymic carcinomas than in type A
thymomas
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ATM is a kinase which induces cell cycle arrest and facil-
itates DNA repair. The inhibition of DNA repair has become
an attractive strategy in cancer therapy. Small molecule inhib-
itors of ATM are currently in preclinical and clinical develop-
ment. Theymay enhance susceptibility of cancer cells to DNA
damaging chemotherapy. Many tumors acquire defects in
DNA damage repair in order to tolerate genomic instability
which is a characteristic of malignant transformation. Defects
in ATM signaling are synthetically lethal with PARP inhibi-
tion, suggesting that combined inhibition of ATM and PARP
may be a therapeutic strategy [23]. PARP inhibitors are ex-
tremely efficient against cancer cells bearing ATM defects, as
shown in the context of mantle cell lymphoma [24, 25].
One thymic carcinoma harbored a NRAS and three type
A thymomas a HRAS mutation. HRAS was the only mutated
gene in type A thymomas in this study. One of the HRAS
mutated cases was a histomorphologically atypical variant
[10] with a lung metastasis. At present the RAS oncogenes
are still not drugable targets, although multiple clinical trials
targeting RAS interacting molecules or downstream signaling
partners are ongoing [26, 27].
We have identified 113 miRNAs that are differently
expessed in type A thymomas and thymic carcinomas.
Thereov, 63 miRNAs belong to two large imprinted miRNA
clusters, namely C19MC on chromosome 19q13.42 [28] and
C14MC on chromosome 14q32 [29]. C19MC overexpression
has been reported in embryonal pediatric brain tumors caused
by fusion with TTYH1 [30] or focal genomic amplification
[31]. Overexpression of this cluster is furthermore observed in
thyroid and parathyroid adenomas, hepatic mesenchymal
hamartomas, hepatocellular carcinomas and a subset of ta-
moxifen resistant breast cancers [32–35]. C19MC overexpres-
sion in type A and AB thymomas has recently been reported
by Radovich M. et al., who suggested that one of the key
functions of the cluster is the activation of the PI3K/AKT
pathway [36]. However, a report by Ucar et al. [37] indicates
that C19MC is also expressed in normal medullary and
cortical thymic epithelial cells. Thus, both of the putative pro-
genitor cell types of TETs express C19MC. We therefore pro-
pose that C19MC expression is silenced in thymic carcino-
mas. This may be caused by promoter methylation [28].
C14MC miRNA expression was decreased in thymic car-
cinomas as compared to type A thymomas, but still present to
some degree, with not all miRNAs of the cluster affected.
Infering from published work suggesting that C14MC func-
tions as a large tumor suppressor cluster in GIST [38] and
glioma [39] we assume that the downregulation of C14MC
miRNAs might exert a tumor promoting effect in thymic
carcinomas.
Among the non-clustered miRNAs with significant differ-
ences in expression between type A thymomas and thymic
carcinomas, the low expression of miR-34b, miR-34c, miR-
130a and miR-195 in thymic carcinomas was most pro-
nounced. These four miRNAs are putative tumor suppressors.
In non-small cell lung cancer (NSCLC) immune evasion of
the tumor via PD-L1 is mediated by miR-34 [40]. A more
frequent PD-L1 protein expression in thymic carcinomas as
compared to type A thymomas has been observed in our study
and might likewise be regulated by miR-34. miR-130a down-
regulation in hepatocellular carcinoma correlates with poor
prognosis [41]. miR-195 prevents cell proliferation and pro-
motes apoptosis by targeting Cyclin D1 and BCL2 and is
decreased in many solid tumors [42, 43].
Among the non-clustered miRNAs overexpressed in thy-
mic carcinoma as compared to type A thymoma miR21, miR-
9-3 and miR-375 were most significant. miR21 is regarded to
be oncogenic. It is upregulated in various solid tumors, lym-
phomas and leukemias [44, 45]. In contrast to our findings in
thymic carcinomas miR-9-3 has been reported to be repressed
by methylation in NSCLC [46]. miR-375 was first identified
as a pancreatic islet-specific miRNA that regulated insulin
secretion [47]. In malignant tumors it is often downregulated
and might constitute a tumor suppressor. In breast and prostate
cancer, however, it is upregulated [48]. Thus, depending on
p=0,0034
p=0,0014 p=0,0002 p=0,0034
Fig. 5 Non-clustered miRNAs
with lower expression in thymic
carcinomas than in type A
thymomas
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the cellular context it may exert an oncogenic influence, prob-
ably also in thymic carcinomas.
Immunohistochemistry was performed to study the expres-
sion of ALK, HER2, HER3, MET, phospho-mTOR,
p16INK4A, PDGFRA, PDGFRB, PD-L1, PTEN and ROS1 in
type A and B3 thymomas and thymic carcinomas. None of the
thymomas and thymic carcinomas analyzed expressed ALK,
HER2 and HER3. The lack of HER2 and HER3 expression in
our samples is in contrast to previous publications. Weissferdt
A. et al. reported HER2 expression in 58 % of 24 squamous
thymic carcinomas. Only a single case showed HER2 gene
amplification by FISH [49]. The authors furthermore de-
scribed HER3 positivity in 45.8 % of the carcinomas. Pan
CC. et al. detected HER2 positivity in nine of 17 thymic car-
cinomas, but no HER2 gene amplification could be demon-
strated by FISH [50]. The reason for these discrepancies in
HER2 and HER3 immunohistochemistry is not known, but
might be attributable to the use of different antibodies and
staining protocols. As can be seen at least from our study
HER2 and HER3 do not constitute a therapeutic target in type
A and B3 thymomas and thymic carcinomas.
The proto-oncogene MET is a receptor tyrosine kinase that
can promote tumor development and progression. Tumors
with MET overexpression, gene amplification and exon 14
skipping mutations are candidates for MET targeted therapies
in clinical trials [51, 52]. A low MET protein expression was
noted in only two type A thymomas, whereas B3 thymomas
and thymic carcinomas did not expressMET. Thus,MET does
not represent a potential therapeutic target in TETs.
Aberrations in the PI3K/mTOR/AKT pathway are com-
mon in solid tumors [53]. Drugs have been developed that
target different components of this pathway. We did not detect
mutations in PIK3CA and AKT1 in type A and B3 thymomas
or thymic carcinomas. Furthermore, the expression of
phospho-mTOR protein did not differ significantly among
type A and B3 thymomas and thymic carcinomas.
PDGFRA was expressed by medullary epithelial cells of
fetal and postnatal normal thymus and by epithelial tumor
cells in 10 analyzed thymomas [54]. A further study [55]
reported PDGFRA protein expression in all 26 thymomas of
various subtypes and 10 thymic carcinomas analyzed.
PDGFRB protein was present in only one third of the tumors,
however, it was not specified whether epithelial cells or stro-
mal cells were positive [55]. In our study the expression of
PDGFRAwas increased in thymic carcinomas as compared to
type A and B3 thymomas. The PDGFRA gene, however, was
not mutated. Aweak PDGFRB positivity was present in a few
type A and B3 thymomas, whereas all thymic carcinomas
were negative. An efficacy of the multi-target tyrosine kinase
inhibitors sorafenib and sunitinib that block also PDGFRA
has been observed in thymic carcinomas [56, 57]. However,
the expression of PDGFRA has not been determined by im-
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possible to conclude whether the efficacy of the drugs was due
to PDGFRA inhibition or blockade of other kinases.
The expression of p16INK4A protein in normal tissue is
generally low. In non-neoplastic thymic tissues we have ob-
served sparce p16iNK4A positive epithelial cells in the vicinity
of Hassall’s corpuscles. In neoplastic cells oncogenic stress
can induce p16INK4A. Furthermore, tumors with loss of the
RB gene or RB protein inactivation by viral oncogenic pro-
teins harbor high levels of p16INK4A [58]. Ten (67 %) of 15
type A thymomas and 14 (47 %) of 30 thymic carcinomas
expressed p16INK4A, whereas only one (6 %) of 17 B3
thymomas was weakly p16INK4A positive. In thymic carcino-
mas a lack of p16INK4A protein expression was largely asso-
ciated with CDKNA gene deletion. In type A thymomas that
lacked CDKN2A deletions and type B3 thymomas that rarely
(7 %) exhibited CDKN2A deletion a different mechanism
must predominate. CDKN2A promoter methylation is a
known alternative mechanism of p16I INK4A silencing and
may dominate in type A and B3 thymomas.
PD-L1 is a molecule that binds to its receptor PD1, which is
expressed on cytotoxic T-cells and exerts an inhibitory effect
[59, 60]. PD-L1 is produced by a fraction of tumors of differ-
ent entities and facilitates their immune escape [59, 60]. The
blockade of the PD-L1/PD-1 interaction with anti-PD1 and
anti-PD-L1 antibodies is a novel therapy with impressive re-
sults in various tumor entities [61]. In our study PD-L1 was
expressed by only 13 % of type A thymomas, but 76 % of B3
thymomas and 53 % of thymic carcinomas. In contrast, a
previous report by Padda et al. [62] that used a different
anti-PD-L1 antibody, described PD-L1 expression in all cases
of TETs. Furthermore, PD-L1 high TETs were associated with
a more aggressive histology and worse prognosis. However,
we did not observe a difference in survival between PD-L1
positive and negative thymic carcinomas. A lack of a differ-
ence in survival between PD-L1 positive and negative TETs
has also been described by Katsuya et al. [63] Considering the
correlation of PD-L1 expression by tumor cells with the like-
lihood of response to anti-PD-1/PD-L1 therapy [64], immune
checkpoint inhibitors might be a novel treatment option for
unresectable or relapsed thymomas and thymic carcinomas.
The expression of PTEN, a phosphatase that negatively
regulates intracellular levels of phosphatidylinositol-3,4,5-
trisphosphate and functions as a tumor suppressor by nega-
tively regulating AKT/mTOR signaling pathways [65], was
heterogenous, with no significant differences between type A
and B3 thymomas and thymic carcinomas. A lack of PTEN
expression was noted in only one B3 thymoma and one thy-
mic carcinoma. However, both tumors retained two PTEN
signals as assesed by FISH. Thus, the lack of PTEN expres-
sion may be caused by an alternative mechanism, like PTEN
promoter methylation [66].
ROS1 is a tyrosine kinase that is aberrantly activated by
translocation in a subset of lung carcinomas and
cholangiocarcinomas. ROS1 translocated tumors frequently
respond to therapy with crizotinib [67]. ROS1 positivity by
immunohistochemistry is a surrogate marker for the presence
of a ROS1 translocation. A weak ROS1 reactivity by immu-
nohistochemistry was noted in three (20%) type A thymomas,
however, they did not harbor a ROS1 translocation as assessed
by FISH. Type B3 thymomas and thymic carcinomas did not
express ROS1. Therefore, ROS1 does not represent a thera-
peutic target in TETs.
In summary, our data show genetic differences between
type A and B3 thymomas and thymic carcinomas with respect
















































































Fig. 7 PD-L1 protein expression in typeA and B3 thymomas and thymic
carcinomas
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furthermore demonstrates that next-generation gene panel se-
quencing of paraffin embedded tissue, which currently enters
diagnostic pathology, combined with FISH and immunohisto-
chemistry can identify potential novel therapeutic targets for
TETs.
Acknowledgments Open access funding provided by Medical
University of Vienna. We are very grateful to Prof. Alexander Marx,
Medical University Mannheim/Heidelberg, for reviewing the histology
of several cases included in this study. Furthermore, we are thankful to Dr.
Ulrike Setinek, Otto Wagner Spital Vienna, for supplying two thymoma
specimens.
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (Eds.)
(2015) WHO classification of tumours of the lung, pleura, thymus
and heart. IARC Press, Lyon
2. Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G (2011) Thymic
malignancies: from clinical management to targeted therapies. J
Clin Oncol: Off J Am Soc Clin Oncol 29(36):4820–4827.
doi:10.1200/Jco.2011.36.0487
3. Schirosi L, Nannini N, Nicoli D, Cavazza A, Valli R, Buti S,
Garagnani L, Sartori G, Calabrese F, Marchetti A, Buttitta F,
Felicioni L, Migaldi M, Rea F, Di Chiara F, Mengoli M, Rossi G
(2012) Activating c-KIT mutations in a subset of thymic carcinoma
and response to different c-KIT inhibitors. Ann Oncol: Off J Eur
Soc Med Oncol / ESMO 23(9):2409–2414.doi:10.1093
/Annonc/Mdr626
4. Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H, Niho
S, Nagai K, Saijo N (2008) Mutational status of EGFR and KIT in
thymoma and thymic carcinoma. Lung Cancer 62(3):316–320
5. Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G,
Gao J, Zucali PA, Calabrese F, Favaretto A, Rea F, Rodriguez-
Canales J, Walker Rl, Pineda M, Zhu YJ, Lau C, Killian KJ,
Bilke S, Voeller D, Dakshanamurthy S, Wang Y, Giaccone G
(2014) A specific missense mutation in GTF2I occurs at high fre-
quency in thymic epithelial tumors. Nat Genet 46 (8):844–849.
doi:10.1038/Ng.3016. http://Www.Nature.Com/Ng/Journal/V46
/N8/Abs/Ng.3016.Html-Supplementary-Information
6. Wang Y, Thomas A, Lau C, Rajan A, Zhu Y, Killian JK, Petrini I,
Pham T, Morrow B, Zhong X, Meltzer PS, Giaccone G (2014)
Mutations of epigenetic regulatory genes are common in thymic
carcinomas. Sci Rep 4:7336. doi:10.1038/Srep07336
7. Moreira AL, Won HH, McMillan R, Huang J, Riely GJ, Ladanyi
M, Berger MF (2015) Massively parallel sequencing identifies re-
current mutations in TP53 in thymic carcinoma associated with
poor prognosis. J Thorac Oncol: Off Publ Int Assoc Study Lung
Cancer 10(2):373–380. doi:10.1097/Jto.0000000000000397
8. Shitara M, Okuda K, Suzuki A, Tatematsu T, Hikosaka Y,
Moriyama S, Sasaki H, Fujii Y, Yano M (2014) Genetic profiling
of thymic carcinoma using targeted next-generation sequencing.
Lung Cancer 86(2):174–179. doi:10.1016/J.Lungcan.2014.08.020
9. Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a
Bioconductor package for differential expression analysis of digital
gene expression data. Bioinformatics 26(1):139–140. doi:10.1093
/Bioinformatics/Btp616
10. Nonaka D, Rosai J (2012) Is there a spectrum of cytologic atypia in
type A thymomas analogous to that seen in type B thymomas? A
pilot study of 13 cases. Am J Surg Pathol 36(6):889–894.
doi:10.1097/Pas.0b013e31824fff50
11. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL
(2011) Cyclin D as a therapeutic target in cancer. Nat Rev Cancer
11(8):558–572. doi:10.1038/Nrc3090
12. Petrini I, Meltzer PS, Zucali PA, Luo J, Lee C, Santoro A, Lee HS,
Killian KJ,WangY, TsokosM, Roncalli M, Steinberg SM,WangY,
Giaccone G (2012) Copy number aberrations of BCL2 and
CDKN2A/B identified by array-CGH in thymic epithelial tumors.
Cell Death Dis 3:E351. http://Www.Nature.Com/Cddis/Journal/V3
/N7/Suppinfo/Cddis201292s1.Html
13. Yamamoto H, Oda Y (2015) Gastrointestinal stromal tumor: recent
advances in pathology and genetics. Pathol Int 65(1):9–18.
doi:10.1111/Pin.12230
14. Ströbel P, Hartmann M, Jakob A, Mikesch K, Brink I, Dirnhofer S,
Marx A (2004) Thymic carcinoma with overexpression of mutated
KIT and the response to imatinib. N Engl J Med 350(25):2625–
2626. doi:10.1056/Nejm200406173502523
15. Bisagni G, Rossi G, Cavazza A, Sartori G, Gardini G, Boni C
(2009) Long lasting response to the multikinase inhibitor bay 43-
9006 (Sorafenib) in a heavily pretreated metastatic thymic carcino-
ma. J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer 4(6):
773–775. doi:10.1097/Jto.0b013e3181a52e25
16. Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E,
Cortes J, Iafrate AJ, Nuciforo P, Tabernero J (2014) Genomic aber-
rations in the FGFR pathway: opportunities for targeted therapies in
solid tumors. Ann Oncol: Off J Eur Soc Med Oncol / ESMO 25(3):
552–563. doi:10.1093/Annonc/Mdt419
17. Liu X, Zhang W, Geng D, He J, Zhao Y, Yu L (2014) Clinical
significance of fibroblast growth factor receptor-3 mutations in
bladder cancer: a systematic review and meta-analysis. Genet Mol
Res: Gmr 13(1):1109–1120. doi:10.4238/2014.February.20.12
18. Ho HK, Yeo AH, Kang TS, Chua BT (2014) Current strategies for
inhibiting FGFR activities in clinical applications: opportunities,
challenges and toxicological considerations. Drug Discov Today
19(1):51–62. doi:10.1016/J.Drudis.2013.07.021
19. Hallberg B, Palmer RH (2013) Mechanistic insight into ALK re-
ceptor tyrosine kinase in human cancer biology. Nat Rev Cancer
13(10):685–700. doi:10.1038/Nrc3580
20. Epstein LF, Chen H, Emkey R, Whittington DA (2012) The
R1275Q neuroblastomamutant and certain ATP-competitive inhib-
itors stabilize alternative activation loop conformations of anaplas-
tic lymphoma kinase. J Biol Chem 287(44):37447–37457.
doi:10.1074/Jbc.M112.391425
21. Modjtahedi H, Cho BC, Michel MC, Solca F (2014) A
comprehensive review of the preclinical efficacy profile of
the ErbB family blocker afatinib in cancer. Naunyn
Schmiedeberg ’s Arch Pharmacol 387(6) :505–521 .
doi:10.1007/S00210-014-0967-3
22. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich
JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y (2009) Analysis
of the tyrosine kinome in melanoma reveals recurrent mutations in
ERBB4. Nat Genet 41(10):1127–1132. doi:10.1038/Ng.438
F. Enkner et al.
23. Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G (2014)
Predictive biomarkers for cancer therapy with PARP inhibitors.
Oncogene 33(30):3894–3907. doi:10.1038/Onc.2013.352
24. Williamson CT, Muzik H, Turhan AG, Zamo A, O’Connor MJ,
Bebb DG, Lees-Miller SP (2010) ATMdeficiency sensitizes mantle
cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
Mol Cancer Ther 9(2):347–357. doi:10.1158/1535-7163.Mct-09-
0872
25. Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer
MJ, Smith G, Powell JE, Rudzki Z, Kearns P,Moss PA, Taylor AM,
Stankovic T (2010) The PARP inhibitor olaparib induces significant
killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
Blood 116(22):4578–4587. doi:10.1182/Blood-2010-01-265769
26. Stephen AG, Esposito D, Bagni RR, McCormick F (2014)
Dragging ras back in the ring. Cancer Cell 25(3):272–281.
doi:10.1016/J.Ccr.2014.02.017
27. Singh H, Longo DL, Chabner BA (2015) Improving prospects for
targeting RAS. J Clin Oncol: Off J Am Soc Clin Oncol 33(31):
3650–3659. doi:10.1200/Jco.2015.62.1052
28. Noguer-Dance M, Abu-Amero S, Al-Khtib M, Lefevre A, Coullin
P, Moore GE, Cavaille J (2010) The primate-specific microRNA
gene cluster (C19MC) is imprinted in the placenta. HumMol Genet
19(18):3566–3582. doi:10.1093/Hmg/Ddq272
29. Morales-Prieto DM, Ospina-Prieto S, Chaiwangyen W,
Schoenleben M, Markert UR (2013) Pregnancy-associated
miRNA-clusters. J Reprod Immunol 97(1):51–61. doi:10.1016/J.
Jri.2012.11.001
30. Kleinman CL, Gerges N, Papillon-Cavanagh S, Sin-Chan P,
Pramatarova A, Quang DAK, Adoue V, Busche S, Caron M,
Djambazian H, Bemmo A, Fontebasso AM, Spence T,
Schwartzentruber J, Albrecht S, Hauser P, Garami M, Klekner A,
Bognar L, Montes JL, Staffa A, Montpetit A, Berube P,
Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel PM,
Duchaine T, Perotti C, Fleming A, Faury D, Remke M, Gallo M,
Dirks P, Taylor MD, Sladek R, Pastinen T, Chan JA, Huang A,
Majewski J, Jabado N (2014) Fusion of TTYH1 with the C19MC
microRNA cluster drives expression of a brain-specific DNMT3B
isoform in the embryonal brain tumor ETMR.Nat Genet 46 (1):39–
4 4 . d o i : 1 0 . 1 0 3 8 / N g . 2 8 4 9 . h t t p : / /Www.N a t u r e .
Com/Ng/Journal/V46/N1/Abs/Ng.2849.Html-Supplementary-
Information
31. Korshunov A, Remke M, Gessi M, Ryzhova M, Hielscher T, Witt
H, Tobias V, Buccoliero AM, Sardi I, Gardiman MP, Bonnin J,
Scheithauer B, Kulozik AE, Witt O, Mork S, Von Deimling A,
Wiestler OD, Giangaspero F, Rosenblum M, Pietsch T, Lichter P,
Pfister SM (2010) Focal genomic amplification at 19q13.42 com-
prises a powerful diagnostic marker for embryonal tumors with
ependymoblastic rosettes. Acta Neuropathol 120(2):253–260.
doi:10.1007/S00401-010-0688-8
32. Cairo S, Wang Y, De Reynies A, Duroure K, Dahan J, Redon MJ,
Fabre M, McClelland M, Wang XW, Croce CM, Buendia MA
(2010) Stem cell-like micro-RNA signature driven by Myc in ag-
gressive liver cancer. Proc Natl Acad Sci U S A 107(47):20471–
20476. doi:10.1073/Pnas.1009009107
33. Flor I, Bullerdiek J (2012) The dark side of a success story:
microRNAs of the C19MC cluster in human tumours. J Pathol
227(3):270–274. doi:10.1002/Path.4014
34. Rippe V, Dittberner L, Lorenz VN, Drieschner N, Nimzyk R, Sendt
W, Junker K, Belge G, Bullerdiek J (2010) The two stem cell
microRNA gene clusters C19MC and miR-371-3 are activated by
specific chromosomal rearrangements in a subgroup of thyroid ad-
enomas. PLoS One 5(3), E9485. doi:10.1371/Journal.
Pone.0009485
35. Vaira V, Elli F, Forno I, Guarnieri V, Verdelli C, Ferrero S, Scillitani
A, Vicentini L, Cetani F, Mantovani G, Spada A, Bosari S, Corbetta
S (2012) The microRNA cluster C19MC is deregulated in
parathyroid tumours. J Mol Endocrinol 49(2):115–124.
doi:10.1530/Jme-11-0189
36. Radovich M, Solzak JP, Hancock BA, Conces ML, Atale R, Porter
RR, Zhu J, Glasscock J, Kesler KA, Badve SS, Schneider BP,
Loehrer PJ (2016) A large microRNA cluster on chromosome 19
is a transcriptional hallmark ofWHO type A and AB thymomas. Br
J Cancer 114(4):477–484. doi:10.1038/Bjc.2015.425
37. Ucar O, Tykocinski LO, Dooley J, Liston A, Kyewski B (2013) An
evolutionarily conserved mutual interdependence between Aire and
microRNAs in promiscuous gene expression. Eur J Immunol 43(7):
1769–1778. doi:10.1002/Eji.201343343
38. Haller F, Von Heydebreck A, Zhang JD, Gunawan B, Langer C,
Ramadori G, Wiemann S, Sahin O (2010) Localization-and muta-
tion-dependent microRNA (miRNA) expression signatures in gas-
trointestinal stromal tumours (GISTs), with a cluster of co-
expressed miRNAs located at 14q32.31. J Pathol 220(1):71–86.
doi:10.1002/Path.2610
39. Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen M,
Cohen M, Zelikovitch B, Shoshan Y, Spektor S, Reubinoff BE,
Felig Y, Gerlitz O, Ben-Hur T, Smith Y, Siegal T (2010) Gliomas
display a microRNA expression profile reminiscent of neural pre-
cursor cells. Neuro-Oncology 12(5):422–433. doi:10.1093
/Neuonc/Nop061
40. Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y,
Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D,
Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh
JW (2016) PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst
108(1). doi:10.1093/Jnci/Djv303
41. Li B, Huang P, Qiu J, Liao Y, Hong J, Yuan Y (2014) MicroRNA-
130a is down-regulated in hepatocellular carcinoma and associates
with poor prognosis. Med Oncol 31(10):230. doi:10.1007/S12032-
014-0230-2
42. Jia LF, Wei SB, Gong K, Gan YH, Yu GY (2013) Prognostic im-
plications of micoRNAmiR-195 expression in human tongue squa-
mous cell carcinoma. PLoS One 8(2), E56634. doi:10.1371
/Journal.Pone.0056634
43. Liu L, Chen L, Xu Y, Li R, Du X (2010) MicroRNA-195 promotes
apoptosis and suppresses tumorigenicity of human colorectal can-
cer cells. Biochem Biophys Res Commun 400(2):236–240.
doi:10.1016/J.Bbrc.2010.08.046
44. Krichevsky AM, Gabriely G (2009) miR-21: a small multi-faceted
RNA. J Cell Mol Med 13(1):39–53. doi:10.1111/J.1582-
4934.2008.00556.X
45. Shen L, Wan Z, Ma Y, Wu L, Liu F, Zang H, Xin S (2015) The
clinical utility of microRNA-21 as novel biomarker for diagnosing
human cancers. Tumour Biol: J Int Soc Oncodevelop Biol Med
36(3):1993–2005. doi:10.1007/S13277-014-2806-Z
46. Heller G, Weinzierl M, Noll C, Babinsky V, Ziegler B,
Altenberger C, Minichsdorfer C, Lang G, Döme B, End-
Pfützenreuter A, Arns BM, Grin Y, Klepetko W, Zielinski
C, Zöchbauer-Müller S (2012) Genome-wide miRNA expres-
sion profiling identifies miR-9-3 and miR-193a as targets for
DNA methylation in non-small cell lung cancers. Clin
Cancer Res: Off J Am Assoc Cancer Res 18(6):1619–1629.
doi:10.1158/1078-0432.Ccr-11-2450
47. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, MacDonald
PE, Pfeffer S, Tuschl T, Rajewsky N, Rorsman P, Stoffel M (2004)
A pancreatic islet-specific microRNA regulates insulin secretion.
Nature 432(7014):226–230. doi:10.1038/Nature03076
48. Yan JW, Lin JS, He XX (2014) The emerging role of miR-375 in
cancer. Int J Cancer 135 (5):1011–1018. doi:10.1002/ijc.28563
49. Weissferdt A, Lin H, Woods D, Tang X, Fujimoto J, Wistuba II,
Moran CA (2012) HER family receptor and ligand status in thymic
carcinoma. Lung Cancer 77(3):515–521. doi:10.1016/J.
Lungcan.2012.05.108
Molecular Profiling of Thymoma and Thymic Carcinoma
50. Pan CC, Chen PCH, Wang LS, Lee JY, Chiang H (2003)
Expression of apoptosis-related markers and HER-2/neu in thymic
epithelial tumours. Histopathology 43(2):165–172
51. Zhang Y, Du Z, Zhang M (2016) Biomarker development in MET-
targeted therapy. Oncotarget 7(24):37370–37389 doi:10.18632
/Oncotarget.8276
52. Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D,
Shivdasani P, Heng JC, Dahlberg SE, Janne PA, Verma S,
Christensen J, Hammerman PS, Sholl LM (2016) MET exon 14
mutations in non-small-cell lung cancer are associated with ad-
vanced age and stage-dependent MET genomic amplification and
c-MET overexpression. J Clin Oncol: Off J Am Soc Clin Oncol
34(7):721–730. doi:10.1200/Jco.2015.63.4600
53. Xu K, Liu P, Wei W (2014) mTOR signaling in tumorigenesis.
Biochimica Et Biophysica Acta 1846(2):638–654. doi:10.1016/J.
Bbcan.2014.10.007
54. Cimpean AM, Ceausu R, Encica S, Gaje PN, Ribatti D, Raica M
(2011) Platelet-derived growth factor and platelet-derived growth
factor receptor-alpha expression in the normal human thymus and
thymoma. Int J Exp Pathol 92(5):340–344. doi:10.1111/J.1365-
2613.2011.00777.X
55. Meister M, Kahl P, Muley T, Morresi-Hauf A, Sebening C, Kern
MA, Breinig M, Schnabel P, Dienemann H, Schirmacher P, Rieker
RJ (2009) Expression and mutational status of PDGFR in thymic
tumours. Anticancer Res 29(10):4057–4061
56. Ströbel P, Bargou R, Wolff A, Spitzer D, Manegold C,
Dimitrakopoulou-Strauss A, Strauss L, Sauer C, Mayer F,
Hohenberger P, Marx A (2010) Sunitinib in metastatic thymic car-
cinomas: laboratory findings and initial clinical experience. Br J
Cancer 103(2):196–200. doi:10.1038/Sj.Bjc.6605740
57. Pagano M, Sierra NM, Panebianco M, Rossi G, Gnoni R, Bisagni
G, Boni C (2014) Sorafenib efficacy in thymic carcinomas seems
not to require c-KIT or PDGFR-alpha mutations. Anticancer Res
34(9):5105–5110
58. Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES (2011) The
meaning of p16(Ink4a) expression in tumors: functional
significance, clinical associations and future developments. Cell
Cycle 10(15):2497–2503
59. Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1
pathway blockade for cancer therapy: mechanisms, response bio-
markers, and combinations. Sci Transl Med 8(328):328rv324.
doi:10.1126/Scitranslmed.Aad7118
60. Topalian SL, Taube JM, Anders RA, Pardoll DM (2016)
Mechanism-driven biomarkers to guide immune checkpoint block-
ade in cancer therapy. Nat Rev Cancer 16(5):275–287. doi:10.1038
/Nrc.2016.36
61. Chen L, Han X (2015) Anti-PD-1/PD-L1 therapy of human cancer:
past, present, and future. J Clin Invest 125(9):3384–3391.
doi:10.1172/Jci80011
62. Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW,
West RB, Wakelee HA (2015) Diffuse high intensity PD-L1 stain-
ing in thymic epithelial tumors. J Thorac Oncol: Off Publ Int Assoc
S t u dy Lung Can c e r 1 0 ( 3 ) : 5 0 0–508 . d o i : 1 0 . 1 097
/Jto.0000000000000429
63. Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K
(2015) Immunohistochemical status of PD-L1 in thymoma and thy-
mic carcinoma. Lung Cancer 88(2):154–159. doi:10.1016/J.
Lungcan.2015.03.003
64. Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive bio-
marker in cancer immunotherapy. Mol Cancer Ther 14(4):847–856.
doi:10.1158/1535-7163.Mct-14-0983
65. Carracedo A, Alimonti A, Pandolfi PP (2011) PTEN level in tumor
suppression: how much is too little? Cancer Res 71(3):629–633.
doi:10.1158/0008-5472.Can-10-2488
66. Roh MR, Gupta S, Park KH, Chung KY, Lauss M, Flaherty KT,
Jönsson G, Rha SY, Tsao H (2016) Promoter methylation of PTEN
is a significant prognostic factor in melanoma survival. J Invest
Dermatol 136(5):1002–1011. doi:10.1016/J.Jid.2016.01.024
67. Ye M, Zhang X, Li N, Zhang Y, Jing P, Chang N, Wu J, Ren X,
Zhang J (2016) ALK and ROS1 as targeted therapy paradigms and
clinical implications to overcome crizotinib resistance. Oncotarget
7(11):12289–12304. doi:10.18632/Oncotarget.6935
F. Enkner et al.
